适应性伺服通风在恶化心力衰竭中的有效性
Takayuki Hidaka1, Takeshi Tada2, Hideaki Suzuki3
1Department of Cardiovascular Internal Medicine, Hiroshima City North Medical Center, Asa Citizens Hospital.
International heart journal
|July 30, 2025
概括
适应性伺服通风 (ASV) 对恶化的心力衰竭 (HF) 患者表现出中性作用,既没有明显的危害,也没有明显的益处. 它在HF管理中的使用需要仔细的临床考虑,因为有效性不确定.
科学领域:
- 心脏病学 心脏病学
- 肺部病理学 肺部病理学
- 医疗技术 医疗技术 医学技术
背景情况:
- 在慢性心力衰竭 (HF) 中管理残留拥堵仍然是一个临床挑战.
- 适应式伺服通风 (ASV) 在日本用于高频拥堵,但其有效性仍有争议.
研究的目的:
- 为了评估ASV在患有心力衰竭恶化的患者中的疗效.
- 评估ASV对HF患者心血管结果的影响.
主要方法:
- 多中心前性观察性SAVIOR-L研究的细分分析.
- 倾向性得分匹配,将96名ASV用户与288名非ASV用户进行比较.
- 对心血管死亡和住院住院的等级组合的赢比分析.
主要成果:
- ASV的胜率是中性的 (0.838在匹配对分析中).
- 分层分析证实了不同HF严重程度的中性效应.
- ASV没有证明确定的危害,但不确定的好处.
结论:
- 在恶化的心力衰竭中使用ASV具有中性的预后效果.
- 在这个人群中,ASV的益处仍然不确定.
- 对ASV的临床应用需要仔细考虑.
相关概念视频
Heart Failure V: Medical Management
25
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
25
Heart Failure VI: Adjunct Therapies
28
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
28
Acute Respiratory Failure-V
209
The treatment for acute respiratory failure varies based on factors like the underlying cause, overall health, and severity. A collaborative healthcare team is essential for early detection, often through arterial blood gas analysis. Identifying the cause is the primary goal, with treatment strategies adjusted for ventilation/perfusion (V/Q) mismatch, shunting, or diffusion impairment.
Ensure that patients are monitored continuously for their response to therapy, including changes in...
Ensure that patients are monitored continuously for their response to therapy, including changes in...
209
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
510
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
510
Heart Failure II: Pathophysiology
44
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
44
Heart Failure Drugs: β-Blockers
435
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
435


